Get the Stockscreener App
5.22
3.98%
0.20
After Hours:
5.23
0.01
+0.19%
Atyr Pharma Inc stock is traded at $5.22, with a volume of 3.32M.
It is up +3.98% in the last 24 hours and down -1.69% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$5.02
Open:
$4.995
24h Volume:
3.32M
Relative Volume:
0.98
Market Cap:
$464.60M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.48%
1M Performance:
-1.69%
6M Performance:
+32.49%
1Y Performance:
+177.66%
1-Day Range:
$4.955
$5.26
1-Week Range:
$4.465
$5.2701
52-Week Range:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.22 | 446.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
aTyr Pharma stock awaits key Phase 3 trial results, Cantor Fitzgerald maintains Overweight rating - Investing.com Canada
aTyr Pharma stock rating reiterated by Cantor Fitzgerald ahead of trial data - Investing.com Canada
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance
Should I hold or sell aTyr Pharma Inc. stock in 2025Free Trading Psychology Coaching - Jammu Links News
Is it the right time to buy aTyr Pharma Inc. stockOutstanding risk-reward balance - Jammu Links News
What drives aTyr Pharma Inc. stock priceDiscover stocks with explosive growth potential - Jammu Links News
What are the technical indicators suggesting about aTyr Pharma Inc.Invest confidently with professional market insights - Jammu Links News
What analysts say about aTyr Pharma Inc. stockAchieve exceptional returns with expert guidance - Jammu Links News
What makes aTyr Pharma Inc. stock price move sharplyDiscover high-impact stocks for your portfolio - Jammu Links News
How does aTyr Pharma Inc. generate profit in a changing economyMaximize your gains with expert trading tips - Jammu Links News
Is aTyr Pharma Inc. stock overvalued or undervaluedBuild a portfolio that withstands market volatility - Jammu Links News
What institutional investors are buying aTyr Pharma Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
Is aTyr Pharma Inc. in Accumulation Phase NowExpert Verified Stock Trade Ideas Backed by Data - metal.it
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Barchart.com
Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), aTyr Pharma (ATYR) and HCA Healthcare (HCA) - The Globe and Mail
Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it
Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
Published on: 2025-07-29 07:01:04 - beatles.ru
aTyr Pharma Inc. Breakout Confirmed by Volume MetricsWatchlist for Smart Swing Trading Updated - metal.it
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it
What is aTyr Pharma Inc. company’s growth strategyMaximize returns with data-driven strategies - Jammu Links News
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - Jammu Links News
How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com
Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - printweek.in
Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - Jammu Links News
RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.40%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):